Celgene Corporation
Subsidiary of Bristol-Myers Squibb (BMY)
Assets
(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Cereblon E3 ubiquitin-ligase · Thalidomide AnalogSmall molecule | Multiple MyelomaFollicular LymphomaMyelodysplastic SyndromesMantle Cell Lymphoma | |
| Approved | HDACSmall molecule | Cutaneous T-Cell Lymphoma | |
| Phase 2 | mTOR (inhibitor)Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
US, FDA · Source ↗
Financial reports
No financial reports recorded.